Indian pharmaceutical company Zydus Cadila has started the phase 1 and 2 human clinical trials for its Covid-19 vaccine candidate 'ZyCoV-D'.
Earlier this month, Zydus had received approval from the Drug Controller General of India (DCGI) to conduct phase 1 and 2 human clinical trials of company's plasmid DNA vaccine candidate for Covid-19.
In a regulatory filing on Wednesday (15 July), Zydus said that it will be enrolling over 1,000 subjects across multiple clinical study sites in India for the trials, reports The Hindu.
The company said that adaptive phase 1 and 2 human clinical trials of ZyCoV-D have commenced with the first human dosing. It added that the adaptive phase 1 and 2 dose escalation, multi-centric study will assess the safety, tolerability and immunogenicity of the vaccine.
Zydus's ZyCov-D is the second Indian Covid-19 vaccine candidate that received DCGI nod for phase 1 and 2 clinical trials.
Earlier in the last week of June, Hyderabad-based Bharat Biotech had announced that its Covid-19 vaccine candidate 'Covaxin' received drug regulator's approval for clinical trials.
The phase 1 and 2 human clinical trials of the Bharat Biotech's Covaxin has also been initiated.
Bharat Biotech has developed the 'Covaxin' in collaboration with Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV), Pune.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.